ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

2:00PM-3:30PM: Abstract Number: 1648

EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging

2:00PM-3:30PM: Abstract Number: 1643

Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1604

First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Abstracts: Antiphospholipid Syndrome

2:00PM-3:30PM: Abstract Number: 1649

Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging

2:00PM-3:30PM: Abstract Number: 1616

Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies

Abstracts: Health Services Research II

2:00PM-3:30PM: Abstract Number: 1642

Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1625

Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning

Abstracts: Pediatric Rheumatology – Clinical II: Connective Tissue Disease

2:00PM-3:30PM: Abstract Number: 1637

IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity

Abstracts: Sjögren’s Syndrome – Basic & Clinical Science

2:00PM-3:30PM: Abstract Number: 1632

Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities

2:00PM-3:30PM: Abstract Number: 1603

Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes

Abstracts: Antiphospholipid Syndrome

2:00PM-3:30PM: Abstract Number: 1601

Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus

Abstracts: SLE – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 1618

Intervention to Improve Medication Adherence Among Patients with SLE

Abstracts: Health Services Research II

2:00PM-3:30PM: Abstract Number: 1634

Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

Abstracts: Sjögren’s Syndrome – Basic & Clinical Science

2:00PM-3:30PM: Abstract Number: 1586

Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing

Abstracts: Innate Immunity

2:00PM-3:30PM: Abstract Number: 1652

Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders

Abstracts: Interprofessional Exemplary

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].